What is the latest official selling price of Zilucoplan in 2025?

Zilucoplan (Zilucoplan) is a new drug for the treatment of myasthenia gravis (MG), especially for adult patients with AChR antibody-positive (AChR-Ab+). Myasthenia gravis is an autoimmune disease that mainly affects the signal transmission between nerves and muscles, causing muscle weakness and fatigue. In severe cases, it can be life-threatening. Zeleptide targets the complement system and inhibits its activity, thereby reducing the attack on neuromuscular junctions, helping to improve patients' clinical symptoms and improve their quality of life.

Clinical studies of zeleptide have shown that the drug has significant efficacy in improving symptoms in patients with myasthenia gravis. During treatment, patients typically experience improvements in muscle strength and increased ability to perform daily activities, which for many patients with myasthenia gravis means greater activity in life. Zeleptide is usually administered by subcutaneous injection, which is easy to use and allows patients to inject it themselves at home, increasing treatment compliance.

Currently, Zeleptide has not yet been launched in China, so domestic patients cannot obtain the drug through formal channels. The current market status also shows that Zeleptide is not included in medical insurance, which makes patients face a high financial burden. In the international market, the price of Zeleptide (16.6 mg/0.416 ml) is approximately between US$20,000 and US$30,000. The specific price may vary due to factors such as different pharmacies, regional differences, and medical insurance policies.

It should be noted that there are currently no generic drugs of zeleptide on the market, which puts patients under greater cost pressure when choosing treatment options. Despite the established clinical effectiveness of zeleptide, patient access to treatment is limited by the lack of affordable alternatives.

Reference materials:https://www.drugs.com/zilucoplan.html